secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2021-11-15T23:59:59+00:00
Accession:  0001193125-21-329003
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen Q3 loss $3.9M, cash $229.9M; ACU193 Phase 1 trial enrolling
------------------------------------------------------------------

- Net loss $3.9M (Q3), $92.3M (9M) including $80.3M non-cash fair-value charges from preferred stock and warrant liabilities.
- Cash and marketable securities $229.9M at Sep 30, 2021 (vs. $43.8M at Dec 2020); IPO net proceeds $168.6M in July 2021.
- R&D expenses $1.8M (Q3), G&A $2.1M; loss from operations $3.9M.
- INTERCEPT-AD Phase 1 trial of ACU193 (anti-AβO antibody) dosed first patient; sentinel safety review passed.
- Topline data expected by end of 2022; COVID-19 Delta variant delayed site activation but recruitment ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000119312521329003/0001193125-21-329003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000119312521329003/d255444d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-329003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer